Early reduction in PD-L1 expression predicts faster treatment response in human cutaneous leishmaniasis
Authors:
- Nidhi S. DeyNDNidhi S. Dey
- Sujai SenaratneSSSujai Senaratne
- Vijani SomaratneVSVijani Somaratne
- Nayani P. MadarasingheNMNayani P. Madarasinghe
- Bimalka SeneviratneBSBimalka Seneviratne
- Sarah ForresterSFSarah Forrester
- Marcela Montes de OcaMOMarcela Montes de Oca
- Luiza Campos ReisLRLuiza Campos Reis
- Srija MoulikSMSrija Moulik
- Pegine B. WalradPWPegine B. Walrad
- Mitali ChatterjeeMCMitali Chatterjee
- Hiro GotoHGHiro Goto
Open Access
- 15 November 2021
- journal article
- research article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 131 (22)
Abstract
Cutaneous leishmaniasis (CL) is caused by Leishmania donovani in Sri Lanka. Pentavalent antimonials (e.g., sodium stibogluconate [SSG]) remain first-line drugs for CL with no new effective treatments emerging. We studied whole blood and lesion transcriptomes from Sri Lankan patients with CL at presentation and during SSG treatment. From lesions but not whole blood, we identified differential expression of immune-related genes, including immune checkpoint molecules, after onset of treatment. Using spatial profiling and RNA-FISH, we confirmed reduced expression of programmed death-ligand 1 (PD-L1) and indoleamine 2,3-dioxygenase 1 (IDO1) proteins on treatment in lesions of a second validation cohort and further demonstrated significantly higher expression of these checkpoint molecules on parasite-infected compared with noninfected lesional CD68+ monocytes and macrophages. Crucially, early reduction in PD-L1 but not IDO1 expression was predictive of rate of clinical cure (HR = 4.88) and occurred in parallel with reduction in parasite load. Our data support a model whereby the initial anti–leishmanial activity of antimonial drugs alleviates checkpoint inhibition on T cells, facilitating immune-drug synergism and clinical cure. Our findings demonstrate that PD-L1 expression can be used as a predictor of rapidity of clinical response to SSG treatment in Sri Lanka and support further evaluation of PD-L1 as a host-directed therapeutic in leishmaniasis.Keywords
All Related Versions
Funding Information
- UK Medical Research Council / UK Aid (MR/P024661/1)
- Welcome Trust (WT104726)
This publication has 37 references indexed in Scilit:
- CD8+ Granzyme B+–Mediated Tissue Injury vs. CD4+IFNγ+–Mediated Parasite Killing in Human Cutaneous LeishmaniasisJournal of Investigative Dermatology, 2013
- Leishmaniasis Worldwide and Global Estimates of Its IncidencePLOS ONE, 2012
- RNAscopeThe Journal of Molecular Diagnostics, 2012
- Leishmaniasis: complexity at the host–pathogen interfaceNature Reviews Microbiology, 2011
- Platelet activation attracts a subpopulation of effector monocytes to sites of Leishmania major infectionJournal of Experimental Medicine, 2011
- Leishmania major Attenuates Host Immunity by Stimulating Local Indoleamine 2,3-Dioxygenase ExpressionThe Journal of Infectious Diseases, 2011
- Leishmania RNA Virus Controls the Severity of Mucocutaneous LeishmaniasisScience, 2011
- B7-H1 Blockade Increases Survival of Dysfunctional CD8+ T Cells and Confers Protection against Leishmania donovani InfectionsPLOS Pathogens, 2009
- Monocyte-Derived Dendritic Cells Formed at the Infection Site Control the Induction of Protective T Helper 1 Responses against LeishmaniaImmunity, 2007
- PD‐L1 and PD‐L2 have distinct roles in regulating host immunity to cutaneous leishmaniasisEuropean Journal of Immunology, 2005